ADAP
Companies
NASDAQ
Adaptimmune Therapeutics plc ADR
Health Care
$0.26
-$0.28 (-52.36%)
Price Chart
Overview
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Market Cap
$260.7M
Volume
689.6K
Avg. Volume
385.1K
P/E Ratio
-0.7560526
Dividend Yield
0.00%
Employees
463.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.43
High Correlation
Volatility
High (0.76)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ADAP shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$260.7M
Volume689.6K
P/E Ratio-0.76
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025